Holmäng S, Hedelin H, Anderström C, Holmberg E, Busch C, Johansson S L
Department of Urology and Oncological Centre, Sahlgrenska University Hospital, Göteborg, Sweden.
J Urol. 1999 Sep;162(3 Pt 1):702-7. doi: 10.1097/00005392-199909010-00019.
We report long-term followup data on patients with World Health Organization (WHO) grade I bladder tumors, and determine whether histopathological subgrouping as papillary neoplasm of low malignant potential and low grade papillary carcinoma is of clinical value.
All 680 patients in western Sweden with first diagnosis of bladder carcinoma in 1987 to 1988 were registered and followed for at least 5 years. Of the tumors 255 (37.5%) were stage Ta, WHO grade I. Tumors were further classified as papillary neoplasm of low malignant potential in 95 patients and low grade papillary carcinoma in 160 according to WHO and the International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the bladder.
Mean age of patients at first diagnosis of low grade papillary carcinoma was 69.2 years, which was 4.6 years higher than those with papillary neoplasm of low malignant potential (p<0.005). During a mean observation time of 60 months our 255 patients underwent 577 operations for recurrences and had 1,858 negative cystoscopies. The risk of recurrence was significantly lower in patients with papillary neoplasm of low malignant potential compared to those with low grade papillary carcinoma (35 versus 71%, p<0.001). The risk of recurrence was higher in patients with multiple tumors at first diagnosis as well as those with recurrence at the first followup after 3 to 4 months. Stage progressed in 6 patients (2.4%), all with low grade papillary carcinoma at diagnosis.
More than 90% of patients with stage Ta, WHO grade I have a benign form of bladder neoplasm, and few have truly malignant tumors. Future research should focus on reducing the number of recurrences and followup cystoscopies, and finding methods to identify malignant tumors so that pertinent treatment can be instituted. Subgrouping of WHO grade I bladder tumors as papillary neoplasm of low malignant potential and low grade papillary carcinoma seems to add valuable prognostic information.
我们报告了世界卫生组织(WHO)I级膀胱肿瘤患者的长期随访数据,并确定将组织病理学亚组分为低恶性潜能乳头状肿瘤和低级别乳头状癌是否具有临床价值。
对1987年至1988年在瑞典西部首次诊断为膀胱癌的所有680例患者进行登记,并随访至少5年。其中255例(37.5%)肿瘤为Ta期,WHO I级。根据WHO和国际泌尿病理学会关于膀胱尿路上皮(移行细胞)肿瘤的共识分类,95例患者的肿瘤进一步分类为低恶性潜能乳头状肿瘤,160例为低级别乳头状癌。
低级别乳头状癌患者首次诊断时的平均年龄为69.2岁,比低恶性潜能乳头状肿瘤患者高4.6岁(p<0.005)。在平均60个月的观察期内,我们的255例患者因复发接受了577次手术,膀胱镜检查阴性1858次。低恶性潜能乳头状肿瘤患者的复发风险明显低于低级别乳头状癌患者(35%对71%,p<0.001)。首次诊断时有多发性肿瘤以及在3至4个月后的首次随访时复发的患者复发风险更高。6例患者(2.4%)出现分期进展,均在诊断时为低级别乳头状癌。
超过90%的Ta期、WHO I级膀胱肿瘤患者患有良性膀胱肿瘤,真正的恶性肿瘤患者很少。未来的研究应集中在减少复发次数和随访膀胱镜检查次数,并找到识别恶性肿瘤的方法以便进行相关治疗。将WHO I级膀胱肿瘤亚分为低恶性潜能乳头状肿瘤和低级别乳头状癌似乎能提供有价值的预后信息。